Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia
1996

Doxorubicin and PSC 833 in Mice with Leukaemia

Sample size: 8 publication Evidence: moderate

Author Information

Author(s): T Colombo, O Gonzalez Paz, M D'Incalci

Primary Institution: Mario Negri Institute for Pharmacological Research

Hypothesis

Does PSC 833 pretreatment modify the pharmacokinetics and anti-tumour activity of doxorubicin in leukaemia models?

Conclusion

PSC 833 increases doxorubicin levels in leukaemic cells but does not reverse resistance in P388/DOX leukaemia.

Supporting Evidence

  • DOX levels were significantly higher in tissues of mice treated with PSC 833.
  • PSC 833 did not reverse the resistance of P388/DOX leukaemia to DOX.
  • Combination treatment increased survival time in P388 leukaemia but not in P388/DOX.

Takeaway

This study looked at how a drug called PSC 833 helps another drug, doxorubicin, work better against cancer in mice, but it didn't help with one type of cancer.

Methodology

Mice were treated with PSC 833 before doxorubicin, and drug levels were measured in tissues and leukaemic cells.

Limitations

The study may not apply to all types of cancer due to the specific resistance mechanisms in P388/DOX leukaemia.

Participant Demographics

BDF1 male mice, approximately 20 grams body weight.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication